Metoprolol Carinopharm (Metoprolol Tartrate)

Metoprolol Tartrate is a selective β1‑adrenergic receptor antagonist. By blocking these receptors in the heart, it reduces sympathetic stimulation, leading to a slower heart rate, decreased contractility, and lower cardiac output. This results in reduced blood pressure and myocardial oxygen consumption, providing therapeutic benefit in cardiovascular disease.

The dosage of Metoprolol Carinopharm is individualized by the prescribing clinician based on the specific indication, patient characteristics, and response to therapy. Healthcare professionals determine the appropriate infusion rate and total daily amount according to clinical guidelines and patient monitoring.

The safety of Metoprolol Carinopharm in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including cold‑chain handling if needed), and assists with import documentation.

Metoprolol is a cardio‑selective (β1‑selective) blocker, offering a lower risk of bronchospasm compared with non‑selective agents such as propranolol. Its intravenous formulation allows rapid titration in acute settings, whereas some alternatives are only available orally. Choice of beta blocker depends on the clinical scenario, comorbidities, and physician preference.

Metoprolol Carinopharm should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Do not store at room temperature for extended periods, as stability may be compromised.

Metoprolol Carinopharm is administered intravenously. The injection is given as a slow infusion or bolus, according to the prescribing clinician’s instructions. Administration should occur in a setting where cardiac monitoring is available, allowing rapid adjustment based on heart rate and blood pressure responses.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible patients, and rare cases of cardiogenic shock. Prompt recognition and management are essential; clinicians should monitor cardiac rhythm, blood pressure, and respiratory status throughout therapy.

Metoprolol Carinopharm is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree AV block without a pacemaker, cardiogenic shock, and uncontrolled severe asthma or COPD where β‑blockade may precipitate bronchospasm.